Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Related Articles
Hoth Therapeutics (NASDAQ: HOTH) Makes Donation to National Eczema Association in Sponsorship of “National Eczema Awareness Month”
October 14, 2019
admin
Newsmakers
Comments Off on Hoth Therapeutics (NASDAQ: HOTH) Makes Donation to National Eczema Association in Sponsorship of “National Eczema Awareness Month”
NEW YORK, Oct. 14, 2019 — Hoth Therapeutics, Inc.(NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]
CytoDyn (OTC: CYDY) Files Pivotal Trial Protocol for HIV Monotherapy with FDA
May 20, 2019
admin
Healthcare, Newsmakers
Comments Off on CytoDyn (OTC: CYDY) Files Pivotal Trial Protocol for HIV Monotherapy with FDA
VANCOUVER, Washington, May 15, 2019 — After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy […]
Frelii, Inc. (OTC: FRLI) Developing personalized medicine using DNA big data & AI
July 9, 2019
admin
CEO Interview, Healthcare
Comments Off on Frelii, Inc. (OTC: FRLI) Developing personalized medicine using DNA big data & AI
Frelii, Inc. (OTC: FRLI), interview with CEO Ian Jenkins discussing the company’s personalized medicine technology which uses human DNA gene sequencing and artificial intelligence (AI) to […]